Bausch + Lomb eyes 2027 trial start for oral dry AMD drug

October 6, 2026 4:30 PM

Bausch + Lomb Corporation (NYSE/TSX: BLCO) announced progress in the development of BL1243 (tonabersat), an investigational oral treatment for dry ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found